Mark Anliker
Long-Term Benefits and Safetyof Systematic Psoriasis Therapy: Swiss Registry on the Treatment of System Psoriasis with Biologics and Systemic Therapeutigs based on PsoBest German Registry and in operational cooperation with CVderm in Hamburg
19.07.2012
Klinische Forschung - 19.07.2012 - 19.07.2012
Automatisch geschlossen
Projektleitung: Anliker Mark
Prospective, Randomized, Partly Blinded, in Part Placebo-controlled, Multicenter, Dose-finding Trial Exploring Safety, Tolerability and Efficacy of a Topical Resiquimod Gel in Patients With Multiple Actinic Keratosis Lesions
19.05.2012Purpose: A Dose-Finding Study of Resiquimod Evaluating Safety and Efficacy in Patients with Multiple Actinic Keratosis Lesions
Klinische Forschung - 19.05.2012 - 19.06.2013
Automatisch geschlossen
Projektleitung: Anliker Mark
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists
19.02.2012The study is a global Phase III, multicenter, randomized, double-blind, placebo controlled, parallel-group study to evaluate the safety and efficacy of omalizumab administered subcutaneously as an add-on therapy for the treatment of adolescent and ad...
Klinische Forschung - 19.02.2012 - 19.06.2013
Automatisch geschlossen
Projektleitung: Anliker Mark
A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled, Parallel Group Study Of The Efficacy And Safety Of 2 Oral Doses Of CP- 690,550 And 1 Subcutaneous Dose Of Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis
15.11.2011Purpose: To evaluate the efficacy of CP-690,550 as compared to etanercept and the safety of CP-690,550 for treatment of moderate to severe chronic plaque psoriasis.
Klinische Forschung - 15.11.2011 - 01.12.2013
Automatisch geschlossen
Projektleitung: Anliker Mark
A Phase 3, Multi-Site, Open-Label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
15.11.2011The main objective of this study is to evaluate the long-term safety of CP-690,550 in patients being treated for moderate to severe chronic plaque psoriasis. This is an open label extension study available to patients who participated in one of the q...
Klinische Forschung - 15.11.2011 - 19.04.2015
Automatisch geschlossen
Projektleitung: Anliker Mark
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety & Tolerability of Two Doses of ACT-128800, an Oral S1P1 Receptor Agonist, Administered up to Twenty-eight Weeks in Patients With Moderate to Severe Chronic Plaque Psoriasis
19.10.2011This study will assess the efficacy, safety and tolerability of two doses of ACT 128800 in patients with moderate-to-severe chronic plaque psoriasis.
Klinische Forschung - 19.10.2011 - 19.09.2012
Automatisch geschlossen
Projektleitung: Anliker Mark
Registerstudie CARPE-CH chronisches Handekzem
19.07.2011Mit dieser Studie sollen wichtige und bisher fehlende Daten zu chronischen Handekzemen strukturiert erhoben werden, durch die neue Erkenntnisse zur Ursache, Therapie und Prognose von Handekzemen zu erwarten sind. Insbesondere sollen dadurch Erkenntni...
Klinische Forschung - 19.07.2011 - 19.07.2013
Automatisch geschlossen
Projektleitung: Anliker Mark